Evaluates the effectiveness of mepolizumab in reducing symptoms of eosinophilic asthma and CRSwNP, indicating potential for improved quality of life.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory disease affecting 2-4% of the population which has a significant impact on quality of life. Approximately 40% to 60% of people with CRSwNP also have eosinophilic asthma, reflecting the unified airway concept characterised by type 2 inflammation driven by interleukin (IL)-4, IL-5 and IL-13.
No takes yet. Share an insight, caveat, or question.
Chiner et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: